NRC FORM 374	NRC	FO	RM	374
--------------	-----	----	----	-----

## U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 3 PAGES Amendment No. 16

## **MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

icensee	

- 1. Daviess Community Hospital
- 2. 1314 East Walnut

P.O. Box 760


Washington, IN 47501

In accordance with letter dated August 1, 2007,

- 3. License number 13-16138-01 is amended in its entirety to read as follows:
- 4. Expiration date November 30, 2010
- 5. Docket No. 030-10475 Reference No.

- 6. Byproduct, source, and/or special nuclear material
  - A. Any byproduct material permitted by 10 CFR 35.100
  - B. Any byproduct material permitted by 10 CFR 35.200
  - C. Any byproduct material permitted by 10 CFR 35.300
  - D. Any byproduct material permitted by 10 CFR 31.11

- 7. Chemical and/or physical form
- 8. Maximum amount that licensee may possess at any one time under this license
  - A. As needed
  - B. As needed
  - C. As needed
  - D. As needed



- 9. Authorized Use:
  - A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
  - B. Any imaging and localization study permitted by 10 CFR 35.200.
  - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300 (excluding procedures requiring hospitalization).
  - D. In vitro studies.

## **CONDITIONS**

- 10. Licensed material shall be used only at the licensee's facilities located at 1314 East Walnut, Washington, Indiana.
- 11. The Radiation Safety Officer for this license is Eung Man Cha, M.D.

U.S. NUCLEAR REGULATORY COMMISSION	1	PAGE	2	of	3	PAGES
	License Number 13-16138-01					
SUPPLEMENTARY SHEET	Docket or Reference Number 030-10475	er				
	Amendment No. 16					
	ATERIALS LICENSE	ATERIALS LICENSE UPPLEMENTARY SHEET  13-16138-01 Docket or Reference Numb 030-10475	License Number 13-16138-01  Docket or Reference Number 030-10475	License Number 13-16138-01  Docket or Reference Number 030-10475	License Number 13-16138-01  Docket or Reference Number 030-10475	License Number 13-16138-01  Docket or Reference Number 030-10475

- 12. Licensed material is only authorized for use by, or under the supervision of:
  - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
  - B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
Eung Man Cha, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding procedures requiring hospitalization) and 31.11
William E. Lehmkuhler, M.D.	10 CFR 35.100, 35.200.
Phillip R. Dawkins, M.D.	10 CFR 35.200.
Justin Q. Ly, M.D.	10 CFR 35.100 and 3 <b>5.200</b> .
Vasdev Lohano, M.D.	Oral administration of sodium iodide I-131 for any uptake, dilution and excretion study or therapy procedure permitted by 10 CFR 35.300, in quantities less than or equal to 33 millicuries.
Gary W. Kerber, M.D.	10 CFR 35.100 and 35.200.

- 13. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
- 14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the limits specified in 10 CFR 30.72 which require consideration of the need for an emergency plan for responding to a release of licensed material.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION	1	PAGE	3	of	3	PAGES
	<b>1</b> =	License Number 13-16138-01					
MATERIALS LICENSE SUPPLEMENTARY SHEET		Docket or Reference Number 030-10475	er				<del></del>
		Amendment No. 16					

- 15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
  - A. Letters dated October 23, 2000 (excluding the Quality Management Program), December 12, 2001, and June 27, 2002.



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

OCT 1 8 2007

Tove L. Simmons

Materials Licensing Branch

Region III